At The Gene Sherpa, Steve Murphy points to a recent perspective in the New England Journal of Medicine that gives direct-to-consumer personal genome services a no-go. Contributing to the lack of enthusiasm for companies like 23andMe and Navigenics is the fear that they offer more uncertainty than anything else when put into the hands of physicians.